Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 198
- Registration Number
- NCT00193596
- Locations
- ๐บ๐ธ
Tower Oncology, Beverly Hills, California, United States
๐บ๐ธClearview Cancer Institute, Huntsville, Alabama, United States
๐บ๐ธJackson Oncology Associates, Jackson, Mississippi, United States
Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT00193609
- Locations
- ๐บ๐ธ
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
๐บ๐ธGreenview Regional Hospital, Bowling Green, Kentucky, United States
๐บ๐ธBaton Rouge General Medical Center, Baton Rouge, Louisiana, United States
Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00193284
- Locations
- ๐บ๐ธ
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2009-01-23
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT00193570
Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-11-13
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 69
- Registration Number
- NCT00193453
- Locations
- ๐บ๐ธ
Gainsville Hematology Oncology Associates, Gainesville, Florida, United States
๐บ๐ธFlorida Cancer Specialists, Fort Myers, Florida, United States
๐บ๐ธNortheast Arkansas Clinic, Jonesboro, Arkansas, United States
Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 94
- Registration Number
- NCT00193258
Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-09-17
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00193622
Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-08-04
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT00193115
Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-08-04
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00193193
Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-07-28
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193401
ยฉ Copyright 2024. All Rights Reserved by MedPath